News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

AmStem Announces Opening of New Operational Headquarters in San Francisco

6/2/2010 1:36:06 PM

SAN FRANCISCO, CA--(Marketwire - June 02, 2010) - AmStem Corporation (OTCBB: AMST), a leading provider of biotherapeutic and cosmetic stem cell products, stem cell collection and storage expertise and access to nanotechnology vital to stem cell research, announced the opening of new Operational Headquarters at 350 Sansome Street Suite 680, San Francisco, CA 94111.

David Stark, President of AmStem International, Inc., commented, "We are excited about getting started on a number of projects now that we have office space and infrastructure for our company. We have secured funding for initial operating expenses, and have secured a Purchase Agreement with Histostem Ltd., of Korea, our sister company, and another subsidiary of the AmStem Corporation. Our first order of business will be to launch U.S. sales of SteMixx, our cosmeceutical facial cream, develop Clinical Trial protocols, and network our Cord Blood Repository with international registries."

About AmStem Corporation
AmStem Corporation (OTCBB: AMST) is in the field of regenerative medicine and is a leading provider of biotherapeutic and cosmetic stem cell products, stem cell collection and storage expertise and access to nanotechnology vital to stem cell research. AmStem owns and operates two subsidiaries: One is a 90% interest of Histostem Co. ltd. (Korean Corporation) and the second is 100% control of AmStem International Inc. (Nevada Corporation).

About Histostem
Histostem is a producer of stem cells utilizing proprietary technology that successfully isolate stem cells from umbilical cord blood (UCB) and nurture them to multipotent stem cells. Histostem also manufactures stem cell based facial creams, possesses storage facilities and conducts clinical research. AmStem International distributes stem cell based cosmetic products. AmStem Corporation acquired 90% of Histostem (a Korean Corporation) through the issuance of 60% of it's then fully diluted outstanding shares.

Information for investors, including an investment profile about AmStem is available at An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors is available at

Forward-Looking Statements
Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for AmStem Corporation may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, successfully complete clinical trials, our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Investor contact:
Hawk Associates
Tom Fox
Tel: +1-305-451-1888

AmStem Corporation
David Stark
Andrew Norstrud

Read at

comments powered by Disqus